Is there a future for other glutamate receptor modulators in the pharmacotherapy of mood disorders?

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023752%3A_____%2F16%3A43915270" target="_blank" >RIV/00023752:_____/16:43915270 - isvavai.cz</a>

Výsledek na webu

<a href="http://ebmh.bmj.com/content/19/3/95.full" target="_blank" >http://ebmh.bmj.com/content/19/3/95.full</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1136/eb-2015-102261" target="_blank" >10.1136/eb-2015-102261</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Is there a future for other glutamate receptor modulators in the pharmacotherapy of mood disorders?

Popis výsledku v původním jazyce

There is increasing evidence that some glutamatergic drugs could have antidepressant effects. Ketamine as a promising prototype for novel glutamatergic antidepressants has a much faster onset of action and is possibly more efficacious than standard antidepressants. The author comments the results of two recent systematic reviews and meta-analyses assessed the antidepressant efficacy (including modes of administration, duration of effect and adverse effects) of ketamine and other glutamate receptor modulators in the treatment of unipolar depression (Caddy et al. 2015 in the Cochrane Database of Systematic Reviews), and, more generally, in mood disorders (Newport et al. 2015 in the American Journal of Psychiatry). In line with findings of previous reviews examining the efficacy of only ketamine, both of the reviews commented on here demonstrated that a single application of a sub-anaesthetic dose of ketamine reliably produces a rapid anti-depressant effect lasting up to 1 week. No evidence was found for the antidepressant efficacy of the other glutamate receptor modulators, even though NMDA partial agonists for the glycine site, D-cycloserine and rapastinel/GLYX-13, had positive effects on mood without causing dissociation. Interestingly, ketamine is also distinguished from the other NMDA antagonists by the frequency of its psychotomimetic and dissociative effects. The vast majority of the studies in these reviews included small sample sizes. Forthcoming ketamine research should continue to examine three central concerns: (1) elucidating ketamine's mechanism of action including the specificity of effect to NMDA antagonism; (2) understanding the administration profile necessary to provide a sustained therapeutic benefit with optimised non-parenteral administration and (3) examining ketamine's long-term safety profile, particularly with repeated and low-dose administration.

Název v anglickém jazyce

Is there a future for other glutamate receptor modulators in the pharmacotherapy of mood disorders?

Popis výsledku anglicky

There is increasing evidence that some glutamatergic drugs could have antidepressant effects. Ketamine as a promising prototype for novel glutamatergic antidepressants has a much faster onset of action and is possibly more efficacious than standard antidepressants. The author comments the results of two recent systematic reviews and meta-analyses assessed the antidepressant efficacy (including modes of administration, duration of effect and adverse effects) of ketamine and other glutamate receptor modulators in the treatment of unipolar depression (Caddy et al. 2015 in the Cochrane Database of Systematic Reviews), and, more generally, in mood disorders (Newport et al. 2015 in the American Journal of Psychiatry). In line with findings of previous reviews examining the efficacy of only ketamine, both of the reviews commented on here demonstrated that a single application of a sub-anaesthetic dose of ketamine reliably produces a rapid anti-depressant effect lasting up to 1 week. No evidence was found for the antidepressant efficacy of the other glutamate receptor modulators, even though NMDA partial agonists for the glycine site, D-cycloserine and rapastinel/GLYX-13, had positive effects on mood without causing dissociation. Interestingly, ketamine is also distinguished from the other NMDA antagonists by the frequency of its psychotomimetic and dissociative effects. The vast majority of the studies in these reviews included small sample sizes. Forthcoming ketamine research should continue to examine three central concerns: (1) elucidating ketamine's mechanism of action including the specificity of effect to NMDA antagonism; (2) understanding the administration profile necessary to provide a sustained therapeutic benefit with optimised non-parenteral administration and (3) examining ketamine's long-term safety profile, particularly with repeated and low-dose administration.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

AN - Psychologie

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Evidence - Based Mental Health: an international digest for mental health clinicians

ISSN

1362-0347

e-ISSN

—

Svazek periodika

19

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

2

Strana od-do

95-96

Kód UT WoS článku

—

EID výsledku v databázi Scopus

2-s2.0-84973355622